-+ 0.00%
-+ 0.00%
-+ 0.00%

PharmaMar Wins Zepzelca Combination Approval in Qatar, Canada, South Korea

MT Newswires·08/03/2026 05:49:34
Listen to the news
05:49 AM EDT, 08/03/2026 (MT Newswires) -- PharmaMar (PHM.MC) received approval from health regulators in Qatar, Canada, and South Korea for Zepzelca, or lurbinectedin, in combination with atezolizumab for the maintenance treatment of adult patients with extensive-stage small cell lung cancer. The approval covers patients whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. The Spanish biopharmaceutical company said the combination of lurbinectedin and atezolizumab is now approved in 18 territories.